Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 plus letrozole as neoadjuvant therapy for HR-positive, HER2-negative stage II-III breast cancer
ChiCTR2200057104Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib and letrozole in breast cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Complete cell cycle arrest, Residual cancer burden and 1 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
dalpiciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200057104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057104.